Praxis Precision Medicines, Inc.
elsunersen
seizures associated with SCN2A Developmental and Epileptic Encephalopathy
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews elsunersen for seizures associated with SCN2A Developmental and Epileptic Encephalopathy around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“The BTD enables expedited development and regulatory review for drugs that are intended to treat a serious condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically signif”